Twain Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $5.96M

  • Investors
  • 2

Twain Therapeutics General Information

Description

Developer of cancer immunotherapy treatment designed for antibody-based IL-2 receptor agonists. The company is developing an antibody that interacts with receptors which promotes a cytotoxic T cell-mediated anti-tumor response with the least side effects, enabling the healthcare industry to offer patients safe and effective therapeutics that address treatment challenges.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Block 531, Upper Cross Street
  • Hong Lim Complex, Number 03-62
  • Singapore, 050531
  • Singapore
Primary Industry
Biotechnology
Corporate Office
  • Block 531, Upper Cross Street
  • Hong Lim Complex, Number 03-62
  • Singapore, 050531
  • Singapore

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Twain Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Seed Round 01-Jun-2022 $5.96M Completed Startup
To view Twain Therapeutics’s complete valuation and funding history, request access »

Twain Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed
To view Twain Therapeutics’s complete cap table history, request access »

Twain Therapeutics Patents

Twain Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026033132-A1 Antigen-binding molecules Pending 09-Aug-2024
WO-2026033134-A1 Antigen-binding molecules Pending 09-Aug-2024
WO-2026033139-A1 Antigen-binding molecules Pending 09-Aug-2024
EP-4646225-A1 Antigen-binding molecules Pending 06-Jan-2023
EP-4646274-A1 Antigen-binding molecules Pending 06-Jan-2023 A61P37/06
To view Twain Therapeutics’s complete patent history, request access »

Twain Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Twain Therapeutics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Accelerate Technologies Corporation Minority
Parker Institute for Cancer Immunotherapy Corporation Minority
To view Twain Therapeutics’s complete investors history, request access »

Twain Therapeutics FAQs

  • When was Twain Therapeutics founded?

    Twain Therapeutics was founded in 2020.

  • Where is Twain Therapeutics headquartered?

    Twain Therapeutics is headquartered in Singapore, Singapore.

  • What is the size of Twain Therapeutics?

    Twain Therapeutics has 6 total employees.

  • What industry is Twain Therapeutics in?

    Twain Therapeutics’s primary industry is Biotechnology.

  • Is Twain Therapeutics a private or public company?

    Twain Therapeutics is a Private company.

  • What is the current valuation of Twain Therapeutics?

    The current valuation of Twain Therapeutics is .

  • What is Twain Therapeutics’s current revenue?

    The current revenue for Twain Therapeutics is .

  • How much funding has Twain Therapeutics raised over time?

    Twain Therapeutics has raised $5.96M.

  • Who are Twain Therapeutics’s investors?

    Accelerate Technologies and Parker Institute for Cancer Immunotherapy have invested in Twain Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process